Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

UK-based drug developer Mission Therapeutics secured $15m in funding yesterday from a consortium led by pharmaceutical firm Pfizer’s strategic investment arm, Pfizer Ventures, that included all its existing investors.

Spun out of University of Cambridge in 2011, Mission is targeting multiple diseases with drug molecules that inhibit deubiquitylating (DUB) enzymes thought to play an integral role in the disruption of several cellular processes.

The company’s lead candidate, USP30, is in preclinical development for indications including acute kidney injury and primary…